美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Corgi All World 2x Daily ETF

24.63

+0.42161.74%

盤後：24.660.0287+0.12%16:10 EDT

成交量：134

成交額：3,301

市值：36.95萬

市盈率：- -

高：24.66

開：24.66

低：24.63

收：24.21

52周最高：25.58

52周最低：20.48

股本：1.50萬

流通股本：1.50萬

量比：0.49

換手率：0.89%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞公告

【券商聚焦】中信證券：上半年CXO及生命科學上游板塊整體表現穩健，CRO有望量價齊升

東北證券：創新藥BD和商業化持續兑現 CXO超預期，傳統板塊築底拐點

分拆上市成利好？金斯瑞大反攻，飆升逾12%！華寶基金港股通醫療ETF（159137）標的指數漲近2%，CXO全線提振

昊海生科：關於參加科創板2026年半年度生物製品及CXO行業集體業績説明會的公告

证券日报网

創新藥三大指數上漲、ETF吸金，CXO及科研服務呈高景氣度

CXO半年報考：行業回暖頭部企業業績普漲 CRDMO一體化優勢顯著行業馬太效應加速顯現

醫療器械迎業績拐點？512170成功收紅！AI4S帶火港股CXO，金斯瑞升逾7%！港股通醫療ETF華寶逆市上揚

東方證券：猴資源將成為國內頭部臨床前CRO核心競爭優勢 CXO量價雙升報表端或大幅改善

招商證券：需求釋放 CXO板塊景氣度明確上行

CXO今天也是支稜起來了

中報業績點燃行情！CXO爆發，藥明合聯、凱萊英績後狂飆！農牧漁重拾攻勢！數字人民幣再擴容！

港股異動 | CRO概念股漲幅居前海外CXO業績普遍超預期機構指全球需求復甦確認

湘財證券：維持藥品行業「買入」評級關注化學制劑、CXO投資機遇

醫藥外包概念盤初普升凱萊英（06821）漲6.21% 機構指CXO行業景氣上行邏輯不斷夯實

創新藥突然啞火，什麼原因？華寶基金港股通創新藥ETF再失半年線，CXO龍頭盡墨，機構:四季度繼續看好醫藥

CXO與創新藥協同共振步入收穫季，借港股通創新藥ETF嘉實一鍵佈局全產業鏈

ETF日報：創新藥與CXO仍然是當前醫藥板塊景氣度最高的兩條主線

CXO概念有支撐凱萊英（06821）漲2.27% 金斯瑞生物科技（01548）漲2.41%

國產創新藥迎三重業績拐點 CXO龍頭利潤與訂單同步創出歷史新高

CXO開啓主升浪，藥明系、金斯瑞、康龍等集體突破！華寶基金港股通醫療ETF創5個月收盤新高，醫療ETF8天7陽

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/WX/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"WX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"WX\",,,,,undefined,":{"symbol":"WX","market":"US","secType":"STK","nameCN":"Corgi All World 2x Daily ETF","latestPrice":24.6313,"timestamp":1789156800000,"preClose":24.2097,"halted":0,"volume":134,"hourTrading":{"tag":"盘后","latestPrice":24.66,"preClose":24.6313,"latestTime":"16:10 EDT","volume":6,"amount":147.7878,"timestamp":1789157404974,"change":0.0287,"changeRate":0.001165,"amplitude":0},"delay":0,"changeRate":0.017414507408187542,"floatShares":15000,"shares":15000,"eps":0,"marketStatus":"未開盤","change":0.4216,"latestTime":"09-11 16:00:00 EDT","open":24.66,"high":24.66,"low":24.6313,"amount":3301,"amplitude":0.001185,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":0,"adr":0,"exchange":"CBOE","adjPreClose":24.2097,"nav":24.19,"aum":362850,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":24.66,"preClose":24.6313,"latestTime":"16:10 EDT","volume":6,"amount":147.7878,"timestamp":1789157404974,"change":0.0287,"changeRate":0.001165,"amplitude":0},"volumeRatio":0.48550745746701046},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"WX\",,,,,undefined,":{"symbol":"WX","floatShares":15000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.48550745746701046,"shares":15000,"dividePrice":0,"high":24.66,"amplitude":0.001185,"preClose":24.2097,"low":24.6313,"week52Low":20.48,"pbRate":"--","week52High":25.58,"institutionHeld":0,"latestPrice":24.6313,"eps":0,"divideRate":0,"volume":134,"delay":0,"ttmEps":0,"open":24.66,"prevYearClose":24.72,"prevWeekClose":25.2148,"prevMonthClose":24.9073,"prevQuarterClose":23.5672,"fiveDayClose":25.243,"twentyDayClose":25.5654,"sixtyDayClose":23.76},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/WX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"WX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"WX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"WX\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666917512","title":"【券商聚焦】中信證券：上半年CXO及生命科學上游板塊整體表現穩健，CRO有望量價齊升","url":"https://stock-news.laohu8.com/highlight/detail?id=2666917512","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666917512?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 09:07","pubTimestamp":1789088866,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券研究指，2026年上半年，CXO板块及生命科学上游板块整体业绩表现稳健，行业进入复苏阶段。上半年海外投融资景气度持续，美联储加息预期走弱，早研板块整体的景气度持续走强，AIDD的快速发展也将进一步催化未来相关实验和验证需求的爆发，该机构认为CRO板块有望量价齐升。CDMO板块上半年龙头业绩表现稳健，整体订单增速持续加快，行业景气度回升。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991341","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06821","WX","03933","01530","LU0244354667.USD","BK0188","06160","09926","LU0540923850.HKD","BK1100","LU0405327494.USD","LU1997245177.USD","LU2328871848.SGD","LU2778985437.USD","LU1997245094.SGD","09688","LU1794554557.SGD","BK1593","06030","LU2476274308.USD","02228","LU0561508036.HKD","LU0348827113.USD","LU0417516902.SGD","BK1500","CXO","LU1146622755.USD","BK0196","LU1969619763.USD","02367","BK1521","SG9999014674.SGD","LU0348783233.USD","LU1188198961.HKD","02196","LU2495084118.USD","02268","LU0463099449.HKD","BK0028","01789","LU0634319403.HKD","LU1720050803.USD","SG9999004311.SGD","01099","600030","IE00B3M56506.USD","BK1574","KURE","LU1997244956.HKD","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666513175","title":"東北證券：創新藥BD和商業化持續兑現 CXO超預期，傳統板塊築底拐點","url":"https://stock-news.laohu8.com/highlight/detail?id=2666513175","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666513175?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 09:55","pubTimestamp":1789005326,"startTime":"0","endTime":"0","summary":"东北证券主要观点如下：创新药板块：海外创新药产业高景气延续，国产药企有望承接红利Pharma依托多元路径实现营收稳健增长，Biotech凭借BD和商业化释放业绩弹性。多家创新药企业2026H1业绩超预期增长，这与CXO板块公司的半年度业绩相印证，进一步确认了板块的中期产业趋势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494239.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK1161","IBBQ","BK0276","BK0028","BK1574","CXO","BK0183","000686","159992","LNGR","MEDX","06978","WX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665934734","title":"分拆上市成利好？金斯瑞大反攻，飆升逾12%！華寶基金港股通醫療ETF（159137）標的指數漲近2%，CXO全線提振","url":"https://stock-news.laohu8.com/highlight/detail?id=2665934734","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665934734?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 14:06","pubTimestamp":1788847560,"startTime":"0","endTime":"0","summary":"CXO概念集体走强，金斯瑞生物科技飙升逾12%，百奥赛图-B涨超9%，泰格医药、凯莱英涨超7%，药明合联涨超4%。港股通医疗ETF华宝标的指数CXO含量超50%，午后涨近2%！全链布局创新药，关注两大T+0交易利器：港股通医疗ETF华宝：被动跟踪港股通医疗主题指数，重仓创新药产业链，50%CXO+20%创新药，其中药明系占比超38%。港股通创新药ETF华宝：被动跟踪恒生港股通创新药精选指数，100%布局创新药研发类公司，7成仓位押注研发龙头。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-08/doc-inirayqy9498188.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["WX","159828","ACTV","CSD","159137","CXO","FLHK","SPIT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665319763","title":"昊海生科：關於參加科創板2026年半年度生物製品及CXO行業集體業績説明會的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2665319763","media":"证券日报网","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665319763?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 18:43","pubTimestamp":1788777780,"startTime":"0","endTime":"0","summary":"证券日报网讯9月7日，昊海生科发布公告称，公司计划于2026年9月15日15：00-17：00参加由上海证券交易所主办的科创板2026年半年度生物制品及CXO行业集体业绩说明会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-07/doc-iniqyzxu6392948.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-07/doc-iniqyzxu6392948.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["WX","BK0239","688366","CXO","BK0251","KSTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665369630","title":"創新藥三大指數上漲、ETF吸金，CXO及科研服務呈高景氣度","url":"https://stock-news.laohu8.com/highlight/detail?id=2665369630","media":"环球网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665369630?lang=zh_tw&edition=fundamental","pubTime":"2026-09-06 09:57","pubTimestamp":1788659820,"startTime":"0","endTime":"0","summary":"H股创新药指数2026上半年收入同比增长17.91%、归母净利润同比增长60.94%、扣非归母净利润同比增长30.73%。银河证券分析称，上半年行业利润增长显著快于收入，主要系创新药商业化收入及对外授权收入增加，高毛利业务占比大幅提升，同时CXO和科研服务呈高景气度，订单增长驱动前期产能建设和人员储备充分利用，摊薄固定成本并推动利润增长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-09-06/doc-iniqvzvc0193188.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["MEDX","BK4585","BK4550","BK1574","IBBQ","LNGR","06978","FDN","WX","BK1161","CXO","BK4588","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664381408","title":"CXO半年報考：行業回暖頭部企業業績普漲 CRDMO一體化優勢顯著行業馬太效應加速顯現","url":"https://stock-news.laohu8.com/highlight/detail?id=2664381408","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664381408?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 14:17","pubTimestamp":1788502620,"startTime":"0","endTime":"0","summary":"近日，头部CXO企业陆续披露半年报。数据显示，国内头部CXO企业大多实现了营收正增长，行业回暖迹象明显。复苏或将逐链传导 行业马太效应加速显现2026年上半年头部CXO企业的业绩分化，本质上是CRDMO一体化模式与单一业务模式之间的较量，是平台型企业与项目型企业之间的差距。从增速来看，药明康德38.93%的营收增速和89.39%的扣非利润增速，在头部企业中均处于领先水平，说明龙头企业不仅规模最大，增长速度也最快，行业马太效应正在加速显现。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-09-04/doc-iniqryes4028570.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["WX","CXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664855519","title":"醫療器械迎業績拐點？512170成功收紅！AI4S帶火港股CXO，金斯瑞升逾7%！港股通醫療ETF華寶逆市上揚","url":"https://stock-news.laohu8.com/highlight/detail?id=2664855519","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664855519?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 19:12","pubTimestamp":1788261120,"startTime":"0","endTime":"0","summary":"9月1日，A股港股医疗板块逆市表现，医疗ETF华宝、港股通医疗ETF华宝等相关品种热度再升温。医疗器械方面，英科医疗上半年营收、净利双增，迈瑞医疗利润降幅显著收窄至5.4%，联影医疗营收同比增长17%。中信建投研报指出，医疗器械行业迎来业绩修复拐点，2026Q2归母净利润实现四年首正增长，板块整体企稳回升。聚焦医疗器械+医疗服务，CXO含量超30%，兼顾脑机接口、AI医疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-01/doc-iniqipis4811448.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["KCAI","159883","LNGR","BK1100","PTH","512170","BK1574","09996","BK4585","WX","MEDX","FLHK","BK4588","GDOC","IEIH","AGNG","MDEV","LGHT","HART","BK1583","VXUS","CXO","RSPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664887541","title":"東方證券：猴資源將成為國內頭部臨床前CRO核心競爭優勢 CXO量價雙升報表端或大幅改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2664887541","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664887541?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 10:36","pubTimestamp":1788230194,"startTime":"0","endTime":"0","summary":"当前，国内食蟹猴供需缺口巨大，若无大规模进口落地，国内猴价或将再创新高，短期看猴资源将成为国内头部临床前CRO的核心竞争优势。该行认为，国内CXO订单充足、量价双升，随着订单执行转化，将会带来报表端大幅改善。相应地，实验猴储备与稳定供给，已成为临床前CRO的核心竞争力。值得注意的是，猴价上行不止是猴子短期供需错配，更是国内临床前CRO新签订单高景气、行业需求反转的真实侧写，猴价将成为影响板块业绩和估值的关键变量。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490154.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK1564","BK0028","03958","BK0276","BK0183","BK0012","WX","BK1147","600958","CXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664896628","title":"招商證券： 需求釋放 CXO板塊景氣度明確上行","url":"https://stock-news.laohu8.com/highlight/detail?id=2664896628","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664896628?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 08:09","pubTimestamp":1788221376,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0276","BK0010","BK0183","BK1564","BK0012","BK1147","06099","CXO","BK0188","WX","600999","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662766810","title":"CXO今天也是支稜起來了","url":"https://stock-news.laohu8.com/highlight/detail?id=2662766810","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662766810?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 09:11","pubTimestamp":1787706660,"startTime":"0","endTime":"0","summary":"来源：硬核姬老板MACD金叉信号形成，这些股涨势不错！","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-26/doc-inipqxha2247730.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["WX","CXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662377731","title":"中報業績點燃行情！CXO爆發，藥明合聯、凱萊英績後狂飆！農牧漁重拾攻勢！數字人民幣再擴容！","url":"https://stock-news.laohu8.com/highlight/detail?id=2662377731","media":"新浪基金","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662377731?lang=zh_tw&edition=fundamental","pubTime":"2026-08-25 19:35","pubTimestamp":1787657700,"startTime":"0","endTime":"0","summary":"盘面上，热点快速轮动，重点关注四个方向：1、CXO方面，中报业绩催化行情，港股药明合联飙涨14.83%创年内新高，凯莱英港股盘中冲上20%，A股涨停封板。药明合联、凯莱英绩后狂飙，港股通医疗ETF爆量大涨，成交额激增超300%】中报业绩持续验证，CXO行情卷土重来！24日，药明合联、凯莱英双双发布2026年中报，上半年经调整归母净利润均实现同比两位数增长，增速分别为37.4%、12.9%。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-25/doc-inipprnn1638871.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159275","06821","BK1191","CNHmain","BK1141","BK0132","MCNHmain","MUCmain","UCmain","SG9999014674.SGD","02268","LU2488822045.USD","BK0239","LU1328615791.USD","WX","CYB","002821","CXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662004362","title":"港股異動 | CRO概念股漲幅居前 海外CXO業績普遍超預期 機構指全球需求復甦確認","url":"https://stock-news.laohu8.com/highlight/detail?id=2662004362","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662004362?lang=zh_tw&edition=fundamental","pubTime":"2026-08-25 10:20","pubTimestamp":1787624451,"startTime":"0","endTime":"0","summary":"消息面上，IQVIA、Medpace、Lonza、三星生物等海外CXO龙头业绩密集披露，订单端强势反转，多家上调全年指引。湘财证券认为，近期CXO整体表现亮眼是全球医药融资回暖下产业基本面持续向好的全球性的趋势，中国CXO相关公司具备工程师红利将充分享受产业红利，在全球产业向好的趋势下持续性预计将较强。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1484814.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0359201612.USD","LU0128526141.USD","LU1794554557.SGD","BK1521","BK4585","LU0572944931.SGD","BK1576","LU0823426480.USD","LU1242518931.SGD","KURE","LU0052750758.USD","LU0327786744.USD","LU0979878070.USD","LU0320764599.SGD","BK4588","LU0516423174.USD","BK1583","LU0307460666.USD","BK1141","03347","LU0708995583.HKD","BK1610","LU1242518857.USD","LU0456827905.SGD","LU0456846285.SGD","06821","WX","LU0417516738.SGD","LU0516422952.EUR","LU0140636845.USD","LU0181495838.USD","LU1880383366.USD","HK0000320223.HKD","LU0348825331.USD","LU0516422440.USD","KCAI","HK0000320264.USD","LU0051755006.USD","LU3063872942.SGD","VXUS","CXO","LU0359202008.SGD","LU2039709279.SGD","LU0029874061.USD","LU0856984785.SGD","02269","LU1688375341.USD","LU0417516902.SGD","01548","LU0823426308.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662007162","title":"湘財證券：維持藥品行業「買入」評級 關注化學制劑、CXO投資機遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2662007162","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662007162?lang=zh_tw&edition=fundamental","pubTime":"2026-08-25 10:17","pubTimestamp":1787624263,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，湘财证券发布研报称，国内药企等正通过Co-Co、NewCo等模式升级，逐步把价值留在国内主体。该行认为，未来一定会诞生更多建立“根据地”的全球化药企，并在其带动下推动板块系统性重估，维持药品行业“买入”评级，建议关注三大主线：布局特定创新药技术平台Biotech公司如小核酸前沿生物;综合性药企;创新药产业链上游CXO、科研试剂。小分子创新药层面可关注Pan-RAS及小核酸药物等机会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1484812.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CXO","161027","WX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662200320","title":"醫藥外包概念盤初普升 凱萊英（06821）漲6.21% 機構指CXO行業景氣上行邏輯不斷夯實","url":"https://stock-news.laohu8.com/highlight/detail?id=2662200320","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662200320?lang=zh_tw&edition=fundamental","pubTime":"2026-08-25 09:57","pubTimestamp":1787623040,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医药外包概念盘初普升，截至发稿，凯莱英 涨6.21%，金斯瑞生物科技涨4.78%，药明生物涨2.22%，维亚生物涨1.67%，泰格医药涨1.05%。消息面上，国金证券表示，CXO行业景气度持续向上，全球生物医药投融资回暖带动创新药研发投入提速，海内外龙头订单与业绩逐步兑现，行业景气上行逻辑不断夯实。头部CXO企业也主动融合AI能力，迭代实验与生产体系。在传统创新药需求叠加AI制药增量的共振之下，行业中长期成长空间进一步打开。","market":"us","thumbnail":"https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989237","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000306685.HKD","LU0039217434.USD","BK1610","LU0140636845.USD","HK0000320264.USD","LU0359201612.USD","06821","LU1794554557.SGD","WX","LU0819121731.USD","159938","LU0326950275.SGD","LU1720050803.USD","LU0051755006.USD","LU0359202008.SGD","BK0132","HK0000320223.HKD","LU0181495838.USD","LU1242518857.USD","LU0856984785.SGD","LU0052750758.USD","LU0516422952.EUR","03347","01873","LU0516423091.SGD","SG9999002463.SGD","BK1191","02269","LU0348825331.USD","LU1242518931.SGD","CXO","LU0029874061.USD","BK1589","BK1161","09939","LU0456846285.SGD","01548","LU0307460666.USD","LU0979878070.USD","BK1515","LU0516422440.USD","LU0708995583.HKD","LU0516422366.SGD","LU0456827905.SGD","002821","KURE","LU0823426308.USD","SG9999002562.SGD","LU1880383366.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661275244","title":"創新藥突然啞火，什麼原因？華寶基金港股通創新藥ETF再失半年線，CXO龍頭盡墨，機構:四季度繼續看好醫藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2661275244","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661275244?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 19:48","pubTimestamp":1787572080,"startTime":"0","endTime":"0","summary":"8月24日，港股深度调整，近期热度较高的医药板块同步走低。100%创新药研发标的——港股通创新药ETF华宝日线连阴，收于半年线下方，全天振幅3.44%，成交3.18亿元。值得一提的是，截至上周，159137在CXO带动连续5周收涨。全链布局创新药，关注两大T+0利器：港股通创新药ETF华宝：被动跟踪恒生港股通创新药精选指数，100%布局创新药研发类公司，7成仓位押注研发龙头。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-24/doc-inipmnps2837356.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IBBQ","WX","BK1161","06978","159316","09939","BK1574","CXO","159992","LNGR","BK1515","FLHK","MEDX","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661922977","title":"CXO與創新藥協同共振步入收穫季，借港股通創新藥ETF嘉實一鍵佈局全產業鏈","url":"https://stock-news.laohu8.com/highlight/detail?id=2661922977","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661922977?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 16:07","pubTimestamp":1787558820,"startTime":"0","endTime":"0","summary":"多家尚未登陆 A 股的创新药、CXO 龙头汇聚港股市场，普通投资者想要把握这一轮产业机遇，或可锚定覆盖港股创新药全产业链、CXO含量较高的港股通创新药ETF嘉实及其联接基金来一键布局。如果场内投资者想高效把握港股创新药和CXO龙头的高景气，港股通创新药ETF嘉实或更适配，其支持场内T+0交易，投资效率更高。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-08-24/doc-inipkzxs2033792.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK1574","WX","CXO","520970","06978","MEDX","159992","LNGR","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660428206","title":"ETF日報：創新藥與CXO仍然是當前醫藥板塊景氣度最高的兩條主線","url":"https://stock-news.laohu8.com/highlight/detail?id=2660428206","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660428206?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 21:08","pubTimestamp":1787231280,"startTime":"0","endTime":"0","summary":"受该里程碑临床进展催化，隔夜莫德纳股价大涨近180%，直接带动A股、港股创新药及疫苗板块情绪回暖。基本面角度，创新药与CXO仍然是当前医药板块景气度最高的两条主线。创新药与CXO板块景气度有望延续，感兴趣的投资者可关注20CM弹性的创业板医药ETF与科创创新药ETF；一键布局港股创新药与CXO龙头的恒生生物科技ETF；以及聚焦A股疫苗相关龙头的疫苗ETF。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-20/doc-ininynce8002615.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LNGR","BK1574","WX","BK1515","BK4585","159992","BK4550","BK1161","06978","BK4588","IBBQ","MEDX","FDN","09939","CXO","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660419923","title":"CXO概念有支撐 凱萊英（06821）漲2.27% 金斯瑞生物科技（01548）漲2.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660419923","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660419923?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 10:53","pubTimestamp":1787108028,"startTime":"0","endTime":"0","summary":"金吾财讯 | CCXO概念有支撑，凯莱英 涨2.27%、金斯瑞生物科技涨2.41%、百济神州涨0.63%、方达控股涨0.79%、药明生物涨0.04%爱建证券表示，2026年初以来医药板块的持续回调与行业基本面、产业趋势发生背离，近期众多上市公司推出现金回购和增持方案，反映出对产业未来发展的充足信心，CXO、创新药及相关产业链已率先发力反弹，医药板块中长期布局良机已至。同时，该机构看好高景气CXO、器械出海、脑机接口、AI+医疗等投资机会。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/ODBhOTU0MzI3NjMwOTM5MjE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ODBhOTU0MzI3NjMwOTM5MjE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988641","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002463.SGD","LU0588546209.SGD","LU0572944931.SGD","002821","HK0000320223.HKD","LU0359202008.SGD","LU0348825331.USD","LU0140636845.USD","LU1969619763.USD","BK1588","LU0819121731.USD","06821","LU0516422440.USD","LU1770034418.SGD","BK1610","LU0708995583.HKD","LU3063872942.SGD","LU1688375341.USD","LU0039217434.USD","LU0417516738.SGD","BK1576","LU0516423091.SGD","BK1589","LU2328871848.SGD","BK1500","KURE","LU0043850808.USD","BK1191","LU0052750758.USD","BK0239","LU0516422366.SGD","CXO","01521","LU1719994722.HKD","LU0320764599.SGD","LU0456827905.SGD","LU0417516902.SGD","02269","LU1242518931.SGD","WX","LU0359201612.USD","LU0228659784.USD","HK0000306685.HKD","BK1141","06160","LU0128526141.USD","LU0181495838.USD","01548","LU1720050803.USD","LU0828237510.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660490014","title":"國產創新藥迎三重業績拐點 CXO龍頭利潤與訂單同步創出歷史新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2660490014","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660490014?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 07:25","pubTimestamp":1787095509,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["WX","MEDX","CXO","IBBQ","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660464424","title":"CXO開啓主升浪，藥明系、金斯瑞、康龍等集體突破！華寶基金港股通醫療ETF創5個月收盤新高，醫療ETF8天7陽","url":"https://stock-news.laohu8.com/highlight/detail?id=2660464424","media":"新浪基金","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660464424?lang=zh_tw&edition=fundamental","pubTime":"2026-08-18 19:45","pubTimestamp":1787053500,"startTime":"0","endTime":"0","summary":"8月18日，CXO强者恒强，继续领涨医疗板块！场内高CXO含量ETF继续上行，港股通医疗ETF华宝标的指数CXO含量全市场第一，场内价格续涨1.25%创5个月收盘新高！全市场规模最大医疗ETF华宝CXO含量超30%，斩获8天7阳。药明康德半年度净利润历史首次突破百亿元大关，并大幅上调全年指引；康龙化成Q2收入和经调利润分别同比增长19.38%和22.3%；昭衍新药上半年归母净利润同比预增884.9%至1377.4%。其中药明系占比超38%。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-18/doc-inintxxh8569801.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159828","FLHK","WX","CXO"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":49,"code":"91000000","status":"200"}]}}